Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (213)

1

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1

enthalten in: Blood | 2024

von Cortes-Selva, D. | Perova, T. | Skerget, S. | +22

2

Monoclonal Antibodies in the Treatment of Multiple Myeloma

enthalten in: Hematology/oncology clinics of North America | 2024

von van de Donk, N. | Zweegman, S.

3

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2024

von Einsele, H. | Moreau, P. | Bahlis, N. | +23

4

Practical Aspects of Immunotherapy : A Report from the 20th International Myeloma Society (IMS) Annual Meeting

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Raje, N. | Cohen, A. | Patel, K. | +3

5

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study

enthalten in: Cancer | 2024

von Nooka, A. | Rodriguez, C. | Mateos, M. | +9

6

Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Martin, T. | Moreau, P. | Usmani, S. | +20

7

Correction : GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

enthalten in: Blood cancer journal | 2024

von Rodriguez-Otero, P. | van de Donk, N. | Pillarisetti, K. | +13

ErratumFor: Blood Cancer J. 2024 Feb 2;14(1):24. - PMID 38307865

8

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2024

von Einsele, H. | Moreau, P. | Bahlis, N. | +23

9

Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2024

von Moreau, P. | Mateos, M. | Gonzalez Garcia, M. | +26

10

GPRC5D as a novel target for the treatment of multiple myeloma : a narrative review

enthalten in: Blood cancer journal | 2024

von Rodriguez-Otero, P. | van de Donk, N. | Pillarisetti, K. | +13

ErratumIn: Blood Cancer J. 2024 Mar 6;14(1):40. - PMID 38448422

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[22]